Protocol Ledger

NCT05537220 · Phase III · ACTIVE NOT RECRUITING

Oral N-acetylcysteine for Retinitis Pigmentosa

Interventional Phase III clinical trial protocol NCT05537220 sponsored by Johns Hopkins University in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-11 Enrollment: 485 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05537220
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)485 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05537220
Protocol FieldVerified Registry Value
NCT IdentifierNCT05537220
Consolidated Lead SponsorJohns Hopkins University
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment485 participants (ACTUAL)
Registered Start Date2023-10-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johns Hopkins Medicine across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI